Defining RASopathy

Overview

Journal Dis Model Mech

Specialty General Medicine

Date 2022 Feb 1

PMID 35103797

Authors

Katherine A Rauen

Affiliations

Soon will be listed here.

Abstract

The term RASopathy was originally created to describe a phenotypically similar group of medical genetic syndromes caused by germline pathogenic variants in components of the RAS/mitogen-activated protein kinase (RAS/MAPK) pathway. In defining a RASopathy syndrome, one needs to consider the complex nature of the RAS/MAPK pathway, the numerous genes and regulatory components involved, its crosstalk with other signaling pathways and the phenotypic spectrum among these syndromes. Three main guiding principles to the definition should be considered. First, a RASopathy is a clinical syndrome with overlapping phenotypic features caused by germline pathogenic variants associated with the RAS/MAPK pathway. Second, a RASopathy is caused by multiple pathogenetic mechanisms, all of which lead to a similar outcome of RAS/MAPK pathway activation/dysregulation. Finally, because a RASopathy has dysfunctional germline RAS/MAPK pathway activation/dysregulation, it may, therefore, be amenable to treatment with pathway modulators.

Citing Articles

Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy.

Qin W, Liu Z, Huang M, Liang L, Gan Y, Huang Z Int J Mol Sci. 2025; 26(4).

PMID: 40003893 PMC: 11855556. DOI: 10.3390/ijms26041425.

Allosteric modulation of NF1 GAP: Differential distributions of catalytically competent populations in loss-of-function and gain-of-function mutants.

Xu L, Jang H, Nussinov R Protein Sci. 2025; 34(2):e70042.

PMID: 39840811 PMC: 11751910. DOI: 10.1002/pro.70042.

Ras, RhoA, and vascular pharmacology in neurodevelopment and aging.

Nussinov R, Jang H, Cheng F Neurochem Int. 2024; 181:105883.

PMID: 39427854 PMC: 11614691. DOI: 10.1016/j.neuint.2024.105883.

Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?.

Healy F, Turner A, Marensi V, MacEwan D Front Pharmacol. 2024; 15:1441938.

PMID: 39372214 PMC: 11450236. DOI: 10.3389/fphar.2024.1441938.

Biomarker Landscape in RASopathies.

Ferrito N, Baez-Flores J, Rodriguez-Martin M, Sastre-Rodriguez J, Coppola A, Isidoro-Garcia M Int J Mol Sci. 2024; 25(16).

PMID: 39201250 PMC: 11354534. DOI: 10.3390/ijms25168563.

References

Brannan C, Perkins A, Vogel K, Ratner N, Nordlund M, Reid S . Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994; 8(9):1019-29. DOI: 10.1101/gad.8.9.1019. View

Champion K, Bunag C, Estep A, Jones J, Bolt C, Rogers R . Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet. 2010; 79(5):468-74. DOI: 10.1111/j.1399-0004.2010.01495.x. View

Evans D, OHara C, Wilding A, Ingham S, Howard E, Dawson J . Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011; 19(11):1187-91. PMC: 3198144. DOI: 10.1038/ejhg.2011.113. View

Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz C, Zenker M . Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol. 2007; 27(22):7765-70. PMC: 2169154. DOI: 10.1128/MCB.00965-07. View

Klomp J, Klomp J, Der C . The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochem Soc Trans. 2021; 49(1):253-267. DOI: 10.1042/BST20200507. View

Hamdan F, Gauthier J, Spiegelman D, Noreau A, Yang Y, Pellerin S . Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N Engl J Med. 2009; 360(6):599-605. PMC: 2925262. DOI: 10.1056/NEJMoa0805392. View

Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R . Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007; 39(9):1120-6. DOI: 10.1038/ng2113. View

Friedman J, Arbiser J, Epstein J, Gutmann D, Huot S, Lin A . Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002; 4(3):105-11. DOI: 10.1097/00125817-200205000-00002. View

Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery R, Berman Y . Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021; 23(8):1506-1513. PMC: 8354850. DOI: 10.1038/s41436-021-01170-5. View

10.

Adviento B, Corbin I, Widjaja F, Desachy G, Enrique N, Rosser T . Autism traits in the RASopathies. J Med Genet. 2013; 51(1):10-20. PMC: 4230531. DOI: 10.1136/jmedgenet-2013-101951. View

11.

Rauen K . The RASopathies. Annu Rev Genomics Hum Genet. 2013; 14:355-69. PMC: 4115674. DOI: 10.1146/annurev-genom-091212-153523. View

12.

Bos J . ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17):4682-9. View

13.

Gripp K, Schill L, Schoyer L, Stronach B, Bennett A, Blaser S . The sixth international RASopathies symposium: Precision medicine-From promise to practice. Am J Med Genet A. 2019; 182(3):597-606. PMC: 7021559. DOI: 10.1002/ajmg.a.61434. View

14.

Li D, March M, Gutierrez-Uzquiza A, Kao C, Seiler C, Pinto E . ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med. 2019; 25(7):1116-1122. DOI: 10.1038/s41591-019-0479-2. View

15.

Dombi E, Baldwin A, Marcus L, Fisher M, Weiss B, Kim A . Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016; 375(26):2550-2560. PMC: 5508592. DOI: 10.1056/NEJMoa1605943. View

16.

Rodriguez-Viciana P, Tetsu O, Tidyman W, Estep A, Conger B, Santa Cruz M . Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006; 311(5765):1287-90. DOI: 10.1126/science.1124642. View

17.

Jafry M, Sidbury R . RASopathies. Clin Dermatol. 2020; 38(4):455-461. DOI: 10.1016/j.clindermatol.2020.03.010. View

18.

Gripp K . Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. 2005; 137C(1):72-7. DOI: 10.1002/ajmg.c.30065. View

19.

Castel P, Cheng A, Cuevas-Navarro A, Everman D, Papageorge A, Simanshu D . RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science. 2019; 363(6432):1226-1230. PMC: 6986682. DOI: 10.1126/science.aav1444. View

20.

Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O . Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999; 18(3):813-22. DOI: 10.1038/sj.onc.1202367. View